[go: up one dir, main page]

MA30801B1 - Biaryl-ether-urees - Google Patents

Biaryl-ether-urees

Info

Publication number
MA30801B1
MA30801B1 MA31798A MA31798A MA30801B1 MA 30801 B1 MA30801 B1 MA 30801B1 MA 31798 A MA31798 A MA 31798A MA 31798 A MA31798 A MA 31798A MA 30801 B1 MA30801 B1 MA 30801B1
Authority
MA
Morocco
Prior art keywords
compounds
biaryl
urea
ether
faah
Prior art date
Application number
MA31798A
Other languages
English (en)
Inventor
Lorraine Kathleen Fay
Douglas Scott Johnson
Scott Edward Lazerwith
Mark Anthony Morris
Lijuan Jane Wang
Marvin Jay Meyers
Suzanne Ross Kesten
Cory Michael Stiff
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39314409&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA30801(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of MA30801B1 publication Critical patent/MA30801B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychology (AREA)
  • Dermatology (AREA)
  • Anesthesiology (AREA)
  • Otolaryngology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

LA PRÉSENTE INVENTION CONCERNE DES COMPOSÉS DE FORMULE (I) (R3)M (I)OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CEUX-CI; DES PROCÉDÉS DE PRÉPARATION DES COMPOSÉS; DES INTERMÉDIAIRES UTILISÉS DANS LA PRÉPARATION DES COMPOSÉS; DES COMPOSITIONS CONTENANT LES COMPOSÉS; ET DES UTILISATIONS DES COMPOSÉS DANS LE TRAITEMENT DE MALADIES OU DE CONDITIONS ASSOCIÉES À L'ACTIVITÉ DE L'HYDROLASE D'AMIDE D'ACIDE GRAS (FAAH).
MA31798A 2006-10-18 2009-04-17 Biaryl-ether-urees MA30801B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US82996606P 2006-10-18 2006-10-18
US96521007P 2007-08-17 2007-08-17

Publications (1)

Publication Number Publication Date
MA30801B1 true MA30801B1 (fr) 2009-10-01

Family

ID=39314409

Family Applications (1)

Application Number Title Priority Date Filing Date
MA31798A MA30801B1 (fr) 2006-10-18 2009-04-17 Biaryl-ether-urees

Country Status (38)

Country Link
US (1) US8044052B2 (fr)
EP (1) EP2076508B1 (fr)
JP (1) JP4434313B2 (fr)
KR (1) KR101181194B1 (fr)
CN (1) CN101595102B (fr)
AP (1) AP2780A (fr)
AR (1) AR063331A1 (fr)
AT (1) ATE493984T1 (fr)
AU (1) AU2007311591B2 (fr)
BR (1) BRPI0717596B8 (fr)
CA (1) CA2663984C (fr)
CL (1) CL2007003000A1 (fr)
CR (2) CR10701A (fr)
CY (1) CY1111170T1 (fr)
DE (1) DE602007011793D1 (fr)
DK (1) DK2076508T3 (fr)
EA (1) EA015488B1 (fr)
ES (1) ES2357340T3 (fr)
GE (1) GEP20125425B (fr)
HN (1) HN2007000407A (fr)
HR (1) HRP20110158T1 (fr)
IL (1) IL197664A (fr)
MA (1) MA30801B1 (fr)
ME (1) ME01308B (fr)
MX (1) MX2009004233A (fr)
MY (1) MY145460A (fr)
NO (1) NO342266B1 (fr)
NZ (1) NZ575624A (fr)
PE (1) PE20081265A1 (fr)
PL (1) PL2076508T3 (fr)
PT (1) PT2076508E (fr)
RS (2) RS51647B (fr)
SI (1) SI2076508T1 (fr)
TN (1) TN2009000138A1 (fr)
TW (1) TWI404715B (fr)
UY (1) UY30649A1 (fr)
WO (1) WO2008047229A2 (fr)
ZA (1) ZA200902548B (fr)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2937341T1 (sl) 2004-12-30 2017-10-30 Janssen Pharmaceutica N.V. Fenilamidni derivati 4-(benzil)-piperazin-1-karboksilne kisline in z njimi povezane spojine kot modulatorji hidrolaze amidov maščobnih kislin (FAAH) za zdravljenje anksioznosti, bolečine in drugih stanj
JO3598B1 (ar) 2006-10-10 2020-07-05 Infinity Discovery Inc الاحماض والاسترات البورونية كمثبطات اميد هيدروليز الحامض الدهني
ATE493984T1 (de) 2006-10-18 2011-01-15 Pfizer Prod Inc Biaryl-ether-harnstoffverbindungen
PE20091838A1 (es) 2008-04-09 2009-12-18 Infinity Pharmaceuticals Inc Inhibidores de amida hidrolasa de acido graso
US20110060012A1 (en) * 2008-04-17 2011-03-10 Pfizer Inc. 4-[3-(aryloxy)benzylidene]-3-methyl piperidine 5-membered aryl carboxamide compounds useful as faah inhibitors
US20110144159A1 (en) * 2008-04-17 2011-06-16 Pfizer Inc Ether benzylidene piperidine aryl carboxamide compounds useful as faah inhibitors
WO2009127949A1 (fr) * 2008-04-17 2009-10-22 Pfizer Inc. Composés aryl carboxamides de 4-[3-(aryloxy)benzylidène]-3-méthyl pipéridine utiles comme inhibiteurs de la faah
WO2009127943A1 (fr) * 2008-04-17 2009-10-22 Pfizer Inc. Composés d'éther-benzylidène-pipéridine-aryl à 5 chaînons-carboxamide utiles comme inhibiteurs de faah
CA2719789A1 (fr) * 2008-04-17 2009-10-22 Pfizer Inc. Composes de 4-benzylidene-3-methylpiperidine-aryl-carboxamide utiles comme inhibiteurs de faah
US8598356B2 (en) 2008-11-25 2013-12-03 Janssen Pharmaceutica Nv Heteroaryl-substituted urea modulators of fatty acid amide hydrolase
WO2010068453A1 (fr) 2008-11-25 2010-06-17 Janssen Pharmaceutica Nv Modulateurs d'urée substitués par hétéroaryle d'amide d'acide gras hydrolase
WO2010064597A1 (fr) * 2008-12-01 2010-06-10 武田薬品工業株式会社 Dérivé de pipéridine
CU24099B1 (es) 2009-01-12 2015-06-30 Pfizer Ltd Derivados de sulfonamida para el tratamiento del dolor
JP2012523425A (ja) 2009-04-07 2012-10-04 インフイニトイ プハルマセウトイカルス インコーポレイテッド 脂肪酸アミドヒドロラーゼの阻害薬
CA2757679A1 (fr) 2009-04-07 2010-10-14 Infinity Pharmaceuticals, Inc. Inhibiteurs d'amide d'hydrolase d'acide gras
US9062116B2 (en) 2009-04-23 2015-06-23 Infinity Pharmaceuticals, Inc. Anti-fatty acid amide hydrolase-2 antibodies and uses thereof
US9149465B2 (en) 2009-05-18 2015-10-06 Infinity Pharmaceuticals, Inc. Isoxazolines as inhibitors of fatty acid amide hydrolase
US8765735B2 (en) 2009-05-18 2014-07-01 Infinity Pharmaceuticals, Inc. Isoxazolines as inhibitors of fatty acid amide hydrolase
US8927551B2 (en) 2009-05-18 2015-01-06 Infinity Pharmaceuticals, Inc. Isoxazolines as inhibitors of fatty acid amide hydrolase
US20120083476A1 (en) 2009-06-05 2012-04-05 Janssen Pharmaceutica Nv Heteroaryl-substituted spirocyclic diamine urea modulators of fatty acid amide hydrolase
WO2010141809A1 (fr) 2009-06-05 2010-12-09 Janssen Pharmaceutica Nv Modulateurs heterocycliques a base d'uree a substitution aryle de l'hydrolase des amides d'acides gras (faah)
ES2626246T3 (es) 2009-09-09 2017-07-24 Sumitomo Dainippon Pharma Co., Ltd. Derivado de 8-oxodihidropurina
WO2011077313A1 (fr) 2009-12-22 2011-06-30 Pfizer Inc. Pipéridinecarboxamides en tant qu'inhibiteurs de mpges - 1
US20130150346A1 (en) 2010-01-08 2013-06-13 Quest Ventures Ltd. Use of FAAH Inhibitors for Treating Parkinson's Disease and Restless Legs Syndrome
RU2569061C2 (ru) 2010-02-03 2015-11-20 Инфинити Фармасьютикалз, Инк. Ингибиторы амид-гидролазы жирных кислот
JP2013520489A (ja) 2010-02-25 2013-06-06 ファイザー・リミテッド ペプチド類似体
WO2011123719A2 (fr) 2010-03-31 2011-10-06 Ironwood Pharmaceuticals, Inc. Utilisation d'inhibiteurs de faah pour le traitement des douleurs abdominales, viscérales et pelviennes
UA108233C2 (uk) 2010-05-03 2015-04-10 Модулятори активності гідролази амідів жирних кислот
EP2590957B1 (fr) 2010-07-09 2014-11-12 Pfizer Limited N-sulfonylbenzamides comme inhibiteurs des canaux sodiques voltage-dépendant
EP2590951B1 (fr) 2010-07-09 2015-01-07 Pfizer Limited Benzènesulfonamides utiles en tant qu'inhibiteurs des canaux sodiques
US9102621B2 (en) 2010-07-12 2015-08-11 Pfizer Limited Acyl sulfonamide compounds
WO2012007868A2 (fr) 2010-07-12 2012-01-19 Pfizer Limited Composés chimiques
EP2593432B1 (fr) 2010-07-12 2014-10-22 Pfizer Limited Dérivés de n-sulfonylbenzamide utiles comme inhibiteurs du canal sodique voltage-dépendant
EP2593427B1 (fr) 2010-07-12 2014-12-24 Pfizer Limited Dérivés de sulfonamides comme inhibiteurs du nav1.7 pour le traitement de la douleur
EP2593433B1 (fr) 2010-07-12 2014-11-26 Pfizer Limited N-sulfonylbenzamides comme inhibiteurs des canaux sodiques voltage-dépendan
WO2012095781A1 (fr) 2011-01-13 2012-07-19 Pfizer Limited Dérivés d'indazole comme inhibiteurs des canaux sodiques
AP2013007159A0 (en) 2011-04-05 2013-10-31 Pfizer Ltd Pyrrolo [2,3-D] pyrimidine derivatives as inhibitors of tropomyosin-related kinase
JP5898767B2 (ja) 2011-07-13 2016-04-06 ファイザー・リミテッドＰｆｉｚｅｒ Ｌｉｍｉｔｅｄ エンケファリン類似体
EP2758375A1 (fr) * 2011-09-23 2014-07-30 Advinus Therapeutics Limited Composés amides, compositions et applications de ceux-ci
WO2013054185A1 (fr) 2011-10-13 2013-04-18 Pfizer, Inc. Dérivés de pyrimidine et de pyridine utiles en thérapie
MD20140037A2 (ro) 2011-10-26 2014-08-31 Pfizer Limited Derivaţi de (4-fenilimidazol-2-il)etilamină utili ca modulatori ai canalului de sodiu
IN2014DN03063A (fr) 2011-10-28 2015-05-15 Inhibitaxin Ltd
US9085517B2 (en) 2011-12-15 2015-07-21 Pfizer Limited Sulfonamide derivatives
WO2013093688A1 (fr) 2011-12-19 2013-06-27 Pfizer Limited Dérivés sulfonamides et leur utilisation en tant qu'inhibiteurs de vgsc
US20150291514A1 (en) 2012-01-04 2015-10-15 Pfizer Limted N-Aminosulfonyl Benzamides
JP6002785B2 (ja) 2012-02-03 2016-10-05 ファイザー・インク ナトリウムチャネルモジュレーターとしてのベンゾイミダゾールおよびイミダゾピリジン誘導体
EP2903989A1 (fr) 2012-10-04 2015-08-12 Pfizer Limited Inhibiteurs de kinase associée à la tropomyosine pyrrolo[2,3-d]pyrimidine
WO2014053965A1 (fr) 2012-10-04 2014-04-10 Pfizer Limited Inhibiteurs de kinases apparentés à la tropomyosine
EP2912036A1 (fr) 2012-10-04 2015-09-02 Pfizer Limited Inhibiteurs de kinase associée à la tropomyosine pyrrolo[3,2-c]pyridine
US9630896B2 (en) 2013-11-22 2017-04-25 Tansna Therapeutics, Inc. 2,5-dialkyl-4-H/halo/ether-phenol compounds
US10421756B2 (en) 2015-07-06 2019-09-24 Rodin Therapeutics, Inc. Heterobicyclic N-aminophenyl-amides as inhibitors of histone deacetylase
HRP20211864T1 (hr) 2015-07-06 2022-03-04 Alkermes, Inc. Inhibitori hetero-halo histonske deacetilaze
ES3025460T3 (en) 2017-01-06 2025-06-09 Janssen Pharmaceutica Nv Scd inhibitor for the treatment of neurological disorders
HRP20220223T1 (hr) 2017-01-11 2022-04-29 Alkermes, Inc. Biciklički inhibitori histon deacetilaze
EP4265597A3 (fr) 2017-06-30 2023-11-22 Amgen Inc. Synthèse d'omecamtiv mecarbil
PL3664802T3 (pl) 2017-08-07 2022-07-11 Alkermes, Inc. Bicykliczne inhibitory deacetylaz histonowych
WO2019173394A1 (fr) 2018-03-05 2019-09-12 Wylder Nation Foundation Compositions et procédés pour activer une signalisation à travers le récepteur cannabinoïde cb1 pour traiter et prévenir des maladies et des troubles caractérisés par une accumulation cellulaire anormale de sphingolipides tels que la sphingomyéline
EA039850B1 (ru) * 2018-04-30 2022-03-21 Эмджен Инк. Синтез омекамтива мекарбила
WO2020038435A1 (fr) * 2018-08-24 2020-02-27 Sunshine Lake Pharma Co., Ltd. Dérivés de pyridinylméthylènepipéridine et leurs utilisations
EA202192047A1 (ru) * 2019-11-13 2021-12-08 Юманити Терапьютикс, Инк. Соединения и их применение
AU2022323513A1 (en) * 2021-08-04 2024-02-22 Jazz Pharmaceuticals Ireland Ltd. Method of treating posttraumatic stress disorder
EP4554674A1 (fr) * 2022-07-15 2025-05-21 Jazz Pharmaceuticals Ireland Limited Composés de biaryl-éther-urée utiles comme inhibiteurs de la faah
WO2024167423A1 (fr) 2023-02-07 2024-08-15 Captor Therapeutics S.A. Composés de dégradation de gspt1
US12410137B2 (en) 2023-07-17 2025-09-09 Apogee Pharmaceuticals, Inc. Fatty acid amide hydrolase modulators, compositions comprising the same and uses thereof

Family Cites Families (100)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB138405A (en) 1919-01-16 1920-02-12 Thomas Thompson Improvements in or relating to suction or delivery valves for pumps
GB1138405A (en) 1966-12-28 1969-01-01 Ici Ltd Morpholine derivatives
US3576810A (en) * 1968-06-20 1971-04-27 Robins Co Inc A H 1-substituted-3-(-4)-aroylpiperidines
GB1260886A (en) 1969-06-20 1972-01-19 Ici Ltd Process for aryloxymethylmorpholine derivatives
BE758766A (fr) 1969-11-17 1971-05-10 Ici Ltd Nouveaux derives de la morpholine et de la
BE759013R (fr) 1969-11-17 1971-05-17 Ici Ltd Derives de la
US4116665A (en) * 1976-04-02 1978-09-26 Eli Lilly And Company Method of regulating the growth of aquatic weeds with pyridine derivatives
IL56369A (en) 1978-01-20 1984-05-31 Erba Farmitalia Alpha-phenoxybenzyl propanolamine derivatives,their preparation and pharmaceutical compositions comprising them
GB8424979D0 (en) * 1984-10-03 1984-11-07 Wyeth John & Brother Ltd Benzenesulphonamide derivatives
GB2167407B (en) 1984-11-22 1988-05-11 Erba Farmitalia Enantiomers of phenoxy derivatives of benzyl morpholine and salts thereof
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
WO1993012107A1 (fr) 1991-12-18 1993-06-24 Schering Corporation Imidazoylalkyle substitue par un cycle heterocyclique contenant de l'azote a six elements
DE4326344A1 (de) 1993-08-05 1995-02-09 Thomae Gmbh Dr K Carbonamide, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
AU7823894A (en) 1993-08-27 1995-03-21 Vrije Universiteit New imidazole derivatives having agonistic or antagonistic activity on the histamine h3 receptor
SK282252B6 (sk) 1995-01-11 2001-12-03 Samjin Pharmaceutical Co., Ltd. Piperazínové deriváty a farmaceutický prostriedok s ich obsahom
US6271015B1 (en) * 1995-06-12 2001-08-07 The Scripps Research Institute Fatty-acid amide hydrolase
GB9526560D0 (en) 1995-12-27 1996-02-28 Bayer Ag Use of 2-Amino-Heterocycles
FR2744449B1 (fr) 1996-02-02 1998-04-24 Pf Medicament Nouvelles piperazines aromatiques derivees de cycloazanes substitues, ainsi que leur procede de preparation, les compositions pharmaceutiques et leur utilisation comme medicaments
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
US6207665B1 (en) 1997-06-12 2001-03-27 Schering Aktiengesellschaft Piperazine derivatives and their use as anti-inflammatory agents
US6184242B1 (en) * 1997-09-04 2001-02-06 Syntex Usa (Llc) 2-(substituted-phenyl)amino-imidazoline derivatives
IL138745A0 (en) 1998-04-01 2001-10-31 Janssen Pharmaceutica Nv Pde iv inhibiting pyridine derivatives
AU764492B2 (en) 1998-12-29 2003-08-21 Pharmacia & Upjohn Company Method for the preparation of aryl ethers
PE20001566A1 (es) 1999-03-26 2001-02-05 Ucb Sa Piperazinas 1,4-sustituidas, piperidinas 1,4-sustituidas y 4-alquilidenilpiperidinas 1-sustituidas
HK1044715B (zh) 1999-03-31 2006-02-17 詹森药业有限公司 在控制释放制剂中的预胶凝淀粉
US6632815B2 (en) * 1999-09-17 2003-10-14 Millennium Pharmaceuticals, Inc. Inhibitors of factor Xa
EP1227090A4 (fr) 1999-10-07 2002-11-20 Tadeka Chemical Ind Ltd Derives d'amines
US6476041B1 (en) 1999-10-29 2002-11-05 Merck & Co., Inc. 1,4 substituted piperidinyl NMDA/NR2B antagonists
KR20020063934A (ko) 2000-01-18 2002-08-07 화이자 프로덕츠 인코포레이티드 코르티코트로핀 방출 인자 길항제
AP2002002596A0 (en) 2000-02-11 2002-09-30 Vertex Pharma Piperazine and piperidine derivatives.
GB0004297D0 (en) * 2000-02-23 2000-04-12 Ucb Sa 2-oxo-1 pyrrolidine derivatives process for preparing them and their uses
CN1426411A (zh) 2000-03-03 2003-06-25 奥索-麦克尼尔药品公司 3－(二芳基亚甲基)－8－氮杂双环[3.2.1]辛烷衍生物
JP2001303987A (ja) * 2000-04-21 2001-10-31 Toyota Motor Corp 筒内噴射式内燃機関のスロットル制御装置
AU2001264376A1 (en) 2000-06-15 2001-12-24 Chaconne Nsi Co., Ltd. Urea derivative useful as an anti-cancer agent and process for preparing same
US20020183316A1 (en) 2000-10-27 2002-12-05 Kevin Pan Amidoalkyl-piperidine and amidoalkyl-piperazine derivatives useful for the treatment of nervous system disorders
AU2002243920A1 (en) 2001-02-08 2002-08-19 Nps Pharmaceuticals, Inc. Methods and compounds for treating neurologic or neuropsychiatric disorders and identifying compounds to treat the same
US20040204477A1 (en) * 2001-07-09 2004-10-14 Juergen Moll Interaction inhibitors of tcf-4 with beta-catenin
AU2002363236A1 (en) 2001-10-30 2003-05-12 Millennium Pharmaceuticals, Inc. Compounds, pharmaceutical compositions and methods of use therefor
US20040034101A1 (en) * 2001-11-05 2004-02-19 Cypress Bioscience, Inc. Treatment and prevention of depression secondary to pain (DSP)
JP3865626B2 (ja) * 2001-11-08 2007-01-10 株式会社ベステックスキョーエイ パイプ部材
FR2833261B1 (fr) * 2001-12-06 2004-07-02 Yang Ji Chemical Company Ltd Nouveaux composes inhibiteurs specifiques de la phospholipase a2 secretee non pancreatique humaine du groupe ii
US20040063726A1 (en) * 2002-02-08 2004-04-01 Artman Linda D Methods and compounds for treating neurologic or neuropsychiatric disorders and identifying compounds to treat the same
WO2003076400A1 (fr) 2002-03-13 2003-09-18 Janssen Pharmaceutica N.V. Nouveaux inhibiteurs de l'histone deacetylase
US6995144B2 (en) 2002-03-14 2006-02-07 Eisai Co., Ltd. Nitrogen containing heterocyclic compounds and medicines containing the same
AU2003220184A1 (en) 2002-03-20 2003-10-08 Schering Aktiengesellschaft Substituted piperazine antithrombotic pai-1 inhibitors
TWI283241B (en) 2002-05-29 2007-07-01 Tanabe Seiyaku Co Novel piperidine compound
JP2006524482A (ja) 2002-10-21 2006-11-02 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 脂肪酸アミド加水分解酵素の活性を測定するためのアッセイ
AR043633A1 (es) * 2003-03-20 2005-08-03 Schering Corp Ligandos de receptores de canabinoides
DE502004009440D1 (de) 2003-04-03 2009-06-10 Merck Patent Gmbh Pyrrolidin-1,2-dicarbonsäure-1-(phenylamid)-2-(4-(3-oxo-morpholin-4-yl)-phenylamid) derivate und verwandte verbindungen als inhibitoren des koagulationsfaktors xa zur behandlung von thromboembolischen erkrankungen
SE0301442D0 (sv) 2003-05-16 2003-05-16 Astrazeneca Ab Diarylmethylidene piperidine derivatives, preparations therof and uses thereof
SE0301443D0 (sv) 2003-05-16 2003-05-16 Astrazeneca Ab Diarylmethylidene piperidine derivatives, preparations thereof and uses thereof
AR045047A1 (es) 2003-07-11 2005-10-12 Arena Pharm Inc Derivados arilo y heteroarilo trisustituidos como moduladores del metabolismo y de la profilaxis y tratamiento de desordenes relacionados con los mismos
GB0325287D0 (en) 2003-10-29 2003-12-03 Merck Sharp & Dohme Therapeutic agents
GB0325956D0 (en) 2003-11-06 2003-12-10 Addex Pharmaceuticals Sa Novel compounds
ES2578254T3 (es) * 2003-12-03 2016-07-22 Ym Biosciences Australia Pty Ltd Inhibidores de cinasas basados en azol
US7435822B2 (en) * 2004-02-03 2008-10-14 Janssen Pharmaceutica N.V. 3-(diheteroarylmethylene)-8-azabicyclo[3.2.1]octane and 3-((aryl)(heteroaryl)methylene)-8-azabicyclo[3.2.1]octane derivatives
WO2005100356A1 (fr) * 2004-04-09 2005-10-27 Merck & Co., Inc. Inhibiteurs de l'activite d'akt
US20080103209A1 (en) * 2004-04-23 2008-05-01 The Regents Of The University Of California Compounds And Methods For Treating Non-Inflammatory Pain Using Ppar Alpha Agonists
SE0401343D0 (sv) 2004-05-25 2004-05-25 Astrazeneca Ab Therapeutic compounds: Pyridine N oxide as scaffold
WO2005121121A2 (fr) 2004-06-04 2005-12-22 Arena Pharmaceuticals, Inc. Derives d'aryle et d'heteroaryle substitues tenant lieu de modulateurs du metabolisme et prevention et traitement de troubles associes
DE102004039789A1 (de) 2004-08-16 2006-03-02 Sanofi-Aventis Deutschland Gmbh Arylsubstituierte polycyclische Amine, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
CA2580845A1 (fr) 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Derives heterocycliques et leur utilisation en tant qu'agents therapeutiques
DE102004045796A1 (de) 2004-09-22 2006-03-23 Merck Patent Gmbh Arzneimittel enthaltend Carbonylverbindungen sowie deren Verwendung
US20090105221A1 (en) 2004-09-29 2009-04-23 Ranbaxy Laboratories Limited Muscarinic receptor antagonists
US7491720B2 (en) * 2004-10-29 2009-02-17 Banyu Pharmaceutical Co., Ltd. Aminopyridine derivatives having Aurora A selective inhibitory action
EP1657241A1 (fr) 2004-11-03 2006-05-17 Schering Aktiengesellschaft Nouveaux urées d' anthranylamide pyridine ayant une activité inhibitrice de kinase du récepteur de VEGF
EP1655297A1 (fr) 2004-11-03 2006-05-10 Schering Aktiengesellschaft Pyridineurées de nicotinamide commes inhibiteurs du recepteur kinase du facteur de croissance endothéliale vasculaire (VEGF)
TW200633990A (en) 2004-11-18 2006-10-01 Takeda Pharmaceuticals Co Amide compound
GT200500375A (es) * 2004-12-20 2006-11-28 Derivados de piperidina y su uso como agentes antiinflamatorios
BRPI0519288A2 (pt) 2004-12-24 2009-01-06 Astrazeneca Ab compostos heterocÍclicos como antagonistas de ccr2b
BRPI0516407A (pt) 2004-12-24 2008-09-02 Prosidion Ltd agonistas de receptor acoplado à proteìna g (gpr116) e uso destes para o tratamento de obesidade e diabetes
SI2937341T1 (sl) 2004-12-30 2017-10-30 Janssen Pharmaceutica N.V. Fenilamidni derivati 4-(benzil)-piperazin-1-karboksilne kisline in z njimi povezane spojine kot modulatorji hidrolaze amidov maščobnih kislin (FAAH) za zdravljenje anksioznosti, bolečine in drugih stanj
EP1851328A1 (fr) 2005-02-10 2007-11-07 Warner-Lambert Company Llc Analyse d'hydrolase d'amide d'acide gras
EP1866314B1 (fr) * 2005-02-16 2010-09-15 NeuroSearch A/S Derives aryle diazabicycliques et utilisation medicale
KR101063663B1 (ko) 2005-02-17 2011-09-07 아스텔라스세이야쿠 가부시키가이샤 피리딜 비방향족 질소 함유 헤테로환-1-카르복실산에스테르유도체
WO2006116773A2 (fr) 2005-04-28 2006-11-02 The Regents Of The University Of California Procedes, compositions et composes de modulation de la lipase de monoacylglycerol, de douleurs et de troubles lies au stress
GB0510139D0 (en) 2005-05-18 2005-06-22 Addex Pharmaceuticals Sa Novel compounds B1
WO2006129842A1 (fr) 2005-06-01 2006-12-07 Banyu Pharmaceutical Co., Ltd. Nouveau derive aminopyridine ayant une activite d’inhibition selective de l’aurora-a
WO2006137465A1 (fr) 2005-06-24 2006-12-28 Shionogi & Co., Ltd. Dérivé hétérocyclique azoté
US7541359B2 (en) * 2005-06-30 2009-06-02 Janssen Pharmaceutica N.V. N-heteroarylpiperazinyl ureas as modulators of fatty acid amide hydrolase
MX2007016508A (es) 2005-06-30 2008-03-04 Prosidion Ltd Agonistas del receptor acoplado a la proteina g.
WO2007023882A1 (fr) 2005-08-26 2007-03-01 Shionogi & Co., Ltd. Dérivé ayant une activité agoniste vis-à-vis du ppar
US7131609B1 (en) 2005-08-31 2006-11-07 Kimberly-Clark Worldwide, Inc. Dispenser for sheet material
US20070155707A1 (en) 2005-12-29 2007-07-05 Kadmus Pharmaceuticals, Inc. Ionizable inhibitors of fatty acid amide hydrolase
WO2007079180A2 (fr) 2005-12-29 2007-07-12 N.V. Organon Inhibiteurs de l’amide hydrolase d’acides gras
US20070259879A1 (en) 2006-03-06 2007-11-08 Trimeris, Inc. Piperazine and piperidine biaryl derivatives
TW200811157A (en) * 2006-05-05 2008-03-01 Astrazeneca Ab mGluR5 modulators I
US20080076924A1 (en) 2006-06-30 2008-03-27 Patrick Betschmann Piperazines as P2X7 antagonists
WO2008024139A2 (fr) 2006-08-18 2008-02-28 N.V. Organon Inhibiteurs d'hydrolase des amides d'acides gras
CA2661085A1 (fr) 2006-08-18 2008-02-21 N.V. Organon Inhibiteur de faah et agent analgesique, anti-inflammatoire ou anti-pyretique combines
US7888394B2 (en) 2006-08-21 2011-02-15 N.V. Organon Synthesis, polymorphs, and pharmaceutical formulation of FAAH inhibitors
JPWO2008023720A1 (ja) 2006-08-23 2010-01-14 アステラス製薬株式会社 ウレア化合物又はその塩
US20080089845A1 (en) 2006-09-07 2008-04-17 N.V. Organon Methods for determining effective doses of fatty acid amide hydrolase inhibitors in vivo
WO2008042892A2 (fr) 2006-10-02 2008-04-10 N.V. Organon Procédé de traitement de troubles du métabolisme énergétique en empêchant l'activité d'un amide hydrolase d'acide gras
JO3598B1 (ar) 2006-10-10 2020-07-05 Infinity Discovery Inc الاحماض والاسترات البورونية كمثبطات اميد هيدروليز الحامض الدهني
ATE493984T1 (de) 2006-10-18 2011-01-15 Pfizer Prod Inc Biaryl-ether-harnstoffverbindungen
US20080119549A1 (en) 2006-11-20 2008-05-22 N.V. Organon Metabolically-stabilized inhibitors of fatty acid amide hydrolase
NZ552238A (en) 2006-12-20 2009-07-31 Seperex Nutritionals Ltd An extract
KR20100017885A (ko) 2007-05-25 2010-02-16 얀센 파마슈티카 엔.브이. 지방산 아미드 하이드롤라아제의 헤테로아릴-치환된 우레아 조절제

Also Published As

Publication number Publication date
NO342266B1 (no) 2018-04-30
TW200825062A (en) 2008-06-16
MY145460A (en) 2012-02-15
NO20091560L (no) 2009-05-15
US8044052B2 (en) 2011-10-25
TWI404715B (zh) 2013-08-11
ATE493984T1 (de) 2011-01-15
DK2076508T3 (da) 2011-02-21
JP4434313B2 (ja) 2010-03-17
US20080261941A1 (en) 2008-10-23
EA200970296A1 (ru) 2009-10-30
BRPI0717596B1 (pt) 2020-04-14
RS20090154A (sr) 2010-10-31
CN101595102A (zh) 2009-12-02
CA2663984C (fr) 2012-02-21
ME01308B (me) 2013-12-20
KR20090061051A (ko) 2009-06-15
KR101181194B1 (ko) 2012-09-18
PL2076508T3 (pl) 2011-05-31
HRP20110158T1 (hr) 2011-04-30
RS51647B (sr) 2011-10-31
HK1139652A1 (en) 2010-09-24
BRPI0717596A2 (pt) 2013-10-29
WO2008047229A3 (fr) 2008-09-04
AU2007311591B2 (en) 2010-10-07
GEP20125425B (en) 2012-03-26
PT2076508E (pt) 2011-03-07
CR10701A (es) 2009-04-30
AP2009004821A0 (en) 2009-04-30
NZ575624A (en) 2012-02-24
ES2357340T3 (es) 2011-04-25
IL197664A (en) 2013-01-31
HN2007000407A (es) 2010-10-04
AR063331A1 (es) 2009-01-21
PE20081265A1 (es) 2008-09-17
EP2076508B1 (fr) 2011-01-05
CL2007003000A1 (es) 2008-06-13
ZA200902548B (en) 2010-03-31
CN101595102B (zh) 2013-08-07
DE602007011793D1 (de) 2011-02-17
TN2009000138A1 (fr) 2010-10-18
AU2007311591A1 (en) 2008-04-24
BRPI0717596B8 (pt) 2021-05-25
CR20140313A (es) 2014-07-28
EA015488B1 (ru) 2011-08-30
SI2076508T1 (sl) 2011-04-29
CA2663984A1 (fr) 2008-04-24
UY30649A1 (es) 2008-05-31
JP2010506896A (ja) 2010-03-04
WO2008047229A2 (fr) 2008-04-24
EP2076508A2 (fr) 2009-07-08
MX2009004233A (es) 2009-08-12
CY1111170T1 (el) 2015-06-11
AP2780A (en) 2013-09-30
IL197664A0 (en) 2009-12-24

Similar Documents

Publication Publication Date Title
MA30801B1 (fr) Biaryl-ether-urees
TN2010000175A1 (fr) Piperidino-dihydrothienopyrimidines substituees
MA30333B1 (fr) Aminotetrahydropyranes utiles en tant qu'inhibiteurs de la dipeptidyle peptidase-iv pour le traitement ou la prevention du diabete.
MA30411B1 (fr) Derives de triazolopyrazine utiles comme agent anticancereux
TNSN04151A1 (fr) Derives de nicotinamide utiles comme inhibiteurs de pde4
MA27774A1 (fr) Inhibiteurs de phosphatidylinositol 3-kinase
MA30289B1 (fr) Dérivés d'amines
MA30403B1 (fr) Derives d'acides cycloalkylamines et leurs compositions pharmaceutiques
MA28681B1 (fr) 3-aminocyclopentanecarboxamides utiles comme modulateurs de récepteurs de chimiokines
TNSN07022A1 (fr) Derives de pyridine
TN2010000230A1 (fr) Agonistes nouveaux des recepteurs de glucocorticoides
MA26697A1 (fr) Composes nouveaux inhibiteurs de gsk-3 et compositions pharmaceutiques les contenant
MA32323B1 (fr) Sulfonamides n-hétérocycliques annelés avec un groupe de tête oxadiazolone, procédés pour leur préparation et leur utilisation en tant qu'agents pharmaceutiques
MA32798B1 (fr) Acides naphtylacétiques
MA30696B1 (fr) Derives de l'acide (3-amino-1,2,3,4-tetrahydro-9h-carbazol-9-yl)-acetique
MA33178B1 (fr) Pipéridines substituées comme antagonistes de ccr3
TNSN99095A1 (fr) 4 - phenylpiperidines nouvelles, procede pour leur preparation et compositions pharmaceutiques les contenant
MA29411B1 (fr) 1h-quinazoline -2,4-diones et leur utilisation en tant que ligands du recepteur ampa
MA28680B1 (fr) 3-aminocyclopentanecarboxamides utiles comme modulateurs de récepteurs de chimiokines
MA29926B1 (fr) Derives de pyrazine
TNSN99031A1 (fr) Composes heterocycliques nouveaux inhibiteurs de romatases, procede pour leur preparation et compositions pharmaceutiques les contenant
ATE538651T1 (de) Spiropiperidininhibitoren von beta-secretase zur behandlung von alzheimer-krankheit
TNSN08137A1 (fr) Derives de carboxamides servant d'antagonistes des recepteurs muscariniques
TN2010000173A1 (fr) Antagonistes de cgrp
MA30313B1 (fr) Amines secondaires en tant qu'inhibiteurs de la renine